Business
Isodiol International Inc. Signs Definitive Agreement to Acquire Bradley’s Bioscience Inc., and Closes Strategic Financing
Isodiol International Inc. Signs Definitive Agreement to Acquire Bradley’s Bioscience Inc., and Closes Strategic Financing.
About this update from Isodiol International Inc
[{"type":"text","content":"\n\n VANCOUVER, British Columbia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a definitive agreement in connection with its previously announced (https://isodiol.com/isodiol-international-signs-letter-intent-acquire-bradleys-bioscience/) Letter of Intent (LOI) to acquire Bradley’s Bioscience Inc., a leading manufacturer and distributer of hemp oil and nicotine e-liquids.\n “The acquisition of Bradley’s Bioscience, a market poised to be a $61.4 billion-dollar industry by 2025 is another major milestone for the Company,” said Marcos Agramont, CEO of Isodiol. “Not only does this allow the Company to penetrate a new market, but we are now also able to provide consumers with a safer alternative to smoking.  Overall, we believe Bradley’s Bioscience is a perfect fit with Isodiol and our long-term vision and we are very pleased to be moving forward with this agreement.” “As we previously stated, Isodiol has been instrumental in our success over the years,” said Joe Bradley, CEO of Bradley’s Bioscience.   “We could not be happier to partner with a company that shares our vision in affecting lives in a positive way and we look forward to continuing to share our message with consumers and the general public.” As part of this agreement, the Company will issue Bradley’s Bioscience Inc. $380,000 USD in stock, which totaled 1,540,281 shares, subject to a 36-month escrow. The Company has also completed an additional round of financing that was initiated prior to our recent escalation in stock price. The intent of the raise is to fund recent acquisitions and allow the company to remain flexible in M&A transactions and future international expansion.  The Company raised a total of $6,087,047 CAD by issuing 24,348,187 units with a full one-year warrant at $.75.  All financing units are subject to a 4 month hold period. For more information on Isodiol, please visit www.isodiol.comFor more information on Bradley’s Bioscience, please visit www.bradleysbrand.com About I...